25 C
New York
Wednesday, July 28, 2021

Natco Pharma soars 17% as path to launch Revlimid generic clears

Must read

U.S. Justice Dept won’t defend Republican lawmaker in Capitol riot lawsuit

Politics17 minutes ago (Jul 27, 2021 09:26PM ET) (C) Reuters. FILE PHOTO: U.S. Rep. Mo Brooks (R-AL) makes an announcement in Huntsville, Alabama, U.S. March...

Gold price today at Rs 46,660 per 10 gm, silver trending at Rs 67,100 a kg

The price of 24-carat gold also declined by Rs 210 to stand at Rs 47,660 per 10 gm ...

Lucro da CSN dispara 1.338,6% no 2º trimestre, para R$ 4,96 bilhões

A CSN registrou lucro atribuído aos controladores de R$ 4,96 bilhões no segundo trimestre deste ano, o que representa alta de 1.338,6%...

MPF: Funai não deve autorizar obras em terra indígena sem consulta ao povo Parakanã

O Ministério Público Federal (MPF) afirmou que a Fundação Nacional do Índio (Funai) e a prefeitura de São Félix do Xingu não...

NEW DELHI: The settlement of Dr Reddy’s Labs with Celgene over its patent on Revlimid cleared the path for Natco to launch the first generic version of the drug which is used to treat multiple myeloma and myelodysplastic syndromes.

Following the settlement, shares of Natco Pharma surged 17.53 per cent to Rs 912.60. During the day it also hit the 20 per cent upper circuit placed at Rs 931.70.

Natco Pharma would be the first company to launch Revlimid (lenalidomide) in March 2022 as Dr Reddy’s settlement clears the path for the company. Dr Reddy’s would launch sometime after it (we assume 6 months) and would have market share restrictions lower than Natco in our view,” said Sriraam Rathi, analyst at ICICI Securities.

Till date, three companies–Natco Pharma, Dr Reddy’s Labs and Alvogen–have settled the litigation with innovator and would launch their respective generics during the exclusivity period of FY23-FY26.

“We expect Natco to generate total revenue and PAT of $1.3 billion and $900 million during the shared exclusivity period over FY23-FY26. This would imply an net present value of Rs302 per share for Revlimid for Natco,” Rathi said.

ICICI Securities also upgraded the stock to ‘buy’ from ‘add’ with target price at Rs 954, up from Rs 875.

Shares of Natco Pharma have surged 53 per cent year-to-date and 60 per cent in the last one year.

- Advertisement -

Latest article

U.S. Justice Dept won’t defend Republican lawmaker in Capitol riot lawsuit

Politics17 minutes ago (Jul 27, 2021 09:26PM ET) (C) Reuters. FILE PHOTO: U.S. Rep. Mo Brooks (R-AL) makes an announcement in Huntsville, Alabama, U.S. March...

Gold price today at Rs 46,660 per 10 gm, silver trending at Rs 67,100 a kg

The price of 24-carat gold also declined by Rs 210 to stand at Rs 47,660 per 10 gm ...

Lucro da CSN dispara 1.338,6% no 2º trimestre, para R$ 4,96 bilhões

A CSN registrou lucro atribuído aos controladores de R$ 4,96 bilhões no segundo trimestre deste ano, o que representa alta de 1.338,6%...

MPF: Funai não deve autorizar obras em terra indígena sem consulta ao povo Parakanã

O Ministério Público Federal (MPF) afirmou que a Fundação Nacional do Índio (Funai) e a prefeitura de São Félix do Xingu não...

Regulamentação sobre lavagem de dinheiro é regulamentada pelo BC

Economia43 minutos atrás (27.07.2021 22:00) Agência Brasil - A legislação de prevenção à lavagem de dinheiro foi atualizada hoje (27) com uma resolução publicada pelo...